Introduction
58% waits for the results before r-HuEPO is prescribed. cells, serum transferrin receptors, zinc protoporphyrins and red cell ferritin concentrations are never mentioned Therefore, 42% accepts the risk to start the expensive r-HuEPO treatment even in cases of frank iron defi-to be the most useful parameter. ciency, which may have not been determined at that time.
Do you monitor iron status regularly during treatment Which iron metabolism parameters do you assess before with r-HuEPO? you start r-HuEPO treatment?
If yes, in what frequency? The results are shown in Table 1 .
All Dutch nephrologists reply that they monitor iron There is general agreement on the importance of status regularly in all patients on r-HuEPO. There is, serum ferritin concentrations for the determination of however, no agreement on the frequency of the assessiron status in haemodialysis patients (98% of all ments, although a majority evaluates iron status every nephrologists uses the measurement). However, many 3 months ( 54%), as recommended by the DGN additional tests are performed, and the respondents do (Table 3 ) . not agree on the choice of these. The determination of red blood cell indices (MCV, MCH, MCHC ) is popular. Transferrin saturation is determined by 44% of the respondents, the percentage hypochromic red blood Which laboratory tests do you perform when the cells, a measurement that has been shown to be very response to r-HuEPO appears to be insuÃcient? informative [3] , only by 6%, and zinc protoporphyrins Except for serum ferritin, serum iron concentration, [6, 7] ( Table 4) . What is, in your opinion, the most useful parameter for determining iron availability?
Although serum ferritin concentration is determined With respect to intravenous iron substitution, Dutch nephrologists appear to be conservative. A minority Forty per cent of the respondents prescribes iron substitution to all patients on r-HuEPO, and 60% on of haemodialysis patients and almost no PD patients received intravenous iron substitution ( Table 7) . indication.
There was no agreement among the respondents on the tests nor the values that determine the necessity Discussion for iron prescription ( Table 5 ).
The monitoring and regulation of iron metabolism are essential in r-HuEPO treatment. Both an absolute and Do you prefer oral iron substitution or intravenous iron a relative iron deficiency may impair the success of the substitution?
therapy [1-4,10,11], with negative eÂects for both the Ninety percent of the respondents prefers oral iron quality of life of the patients and the costs. substitution; 10% intravenous iron. However, 27% sometimes prescribes intravenous iron without a previ- other parameters ( Table 6 ). Iron metabolism can be evaluated on three diÂerent believe that this will be diÂerent among colleagues in other countries. This is sad, since an adequate managelevels. Serum ferritin concentration predicts the ment of iron metabolism may result in a substantial amount of iron stored in the body. Serum iron concendecrease of the r-HuEPO dose (and the budget!), and tration and transferrin saturation estimate the availaba better eÃcacy in many patients. Recently, a protocol ility of iron for the erythron at the level of the serum.
reflecting current knowledge has been proposed in this The percentage hypochromic red blood cells, zinc journal [10] , that will hopefully result in an improved protoporphyrin concentration, erythrocyte ferritin contreatment of patients with the anaemia of end-stage centration, and serum transferrin receptor concentrarenal disease and, at least, less confusion among tion estimate the need for iron at the level of the nephrologists. The DGN is currently working on a erythron and the eÃciency of iron incorporation into new protocol for the Dutch dialysis physicians. the protoporphyrin molecule.
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[3 ], zinc protoporphyrin concentration [6, 7] , serum transferrin receptor concentration [8 ] 
